Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

212 trials

NCT07233291
Recruiting
A Pilot Study to Assess How Safe and Effective Oral Roflumilast is for Treating Moderate to Severe Psoriasis in Adults
Phase 2 · Egypt · 1 site
Registry update: 2 Dec 2025
NCT07141004
Recruiting
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
Phase 4 · India · 11 sites
Registry update: 28 Aug 2026
NCT07320872
Recruiting
Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris
Not applicable · Egypt · 1 site
Registry update: 6 Jan 2026
NCT07169019
Recruiting
Microbiome and Clinical Response to Probiotics and Methotrexate in Early Psoriasis: a Pilot Study
Early phase 1 · Egypt · 1 site
Registry update: 11 Sept 2025
NCT07128472
Recruiting
Evaluation of IL 12B Genetic Polymorphism (rs3213094)
Not applicable · Egypt · 1 site
Registry update: 19 Aug 2025
NCT07879885
Recruiting
An Open-label Study of HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis
Phase 2 · China · 1 site
Registry update: 20 Oct 2026
NCT07149792
Recruiting
A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers
Phase 4 · Taiwan · 2 sites
Registry update: 2 Sept 2025
NCT07021495
Recruiting
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
Not applicable · Netherlands · 8 sites
Registry update: 19 Aug 2025
2024-514647-29-01
Recruiting
Early intervention in plaque psoriasis: is bimekizumab able to delay chronic inflammation? Prospective multicenter interventional study
Phase 2 · France · 8 sites
Registry update: 5 Aug 2026
NCT06742333
Recruiting
Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation?
Phase 2 · France · 7 sites
Registry update: 1 Oct 2026
NCT07166315
Recruiting
Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
Not applicable · United Kingdom · 1 site
Registry update: 27 Oct 2026
NCT06982352
Recruiting
Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
Phase 1 · Jordan, United States · 3 sites
Registry update: 19 Dec 2025
NCT06786936
Recruiting
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
Not applicable · United Kingdom · 1 site
Registry update: 19 Jun 2025
NCT07086924
Recruiting
Genetic Variation in TRAF3IP2 (rs13190932)
Not applicable · Egypt · 1 site
Registry update: 25 Jul 2025
NCT06586281
Recruiting
Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab Therapy
Not applicable · United States · 1 site
Registry update: 10 Jun 2026
NCT07033234
Recruiting
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics and Food Effect of HS-20118
Phase 1 · China · 1 site
Registry update: 24 Jun 2025
NCT07038720
Recruiting
A Study of UA026 Tablets in Healthy Adult Subjects and Adult Subjects With Moderate to Severe Plaque Psoriasis
Phase 1 · China · 1 site
Registry update: 17 Nov 2025
NCT07718815
Recruiting
HLA B Leader in Patients With Psoriatic Arthritis
Not applicable · France · 1 site
Registry update: 22 Jul 2026
NCT06987292
Recruiting
A Prospective Study to Assess the Efficacy of IL-17 Inhibitors on Subclinical Enthesitis in Patients With Moderate to Severe Psoriasis Based on Power Doppler (PD) Ultrasonography (PDUS)
Not applicable · China · 1 site
Registry update: 23 May 2025
NCT07615712
Recruiting
PPD™ CorEvitas™ Psoriasis (PSO) Rapid Response Non-Interventional Study
Not applicable · United States · 1 site
Registry update: 26 Aug 2026

Ordered by registry start date. Freshness and sponsorship never change the order.